Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Abraham

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
The Indian Journal of Medical Research|May 5, 2020
First isolation of SARS-CoV-2 from clinical samples in IndiaPrasad Sarkale, Savita Patil, Pragya D Yadav, et al.
The Lancet. Infectious Diseases|January 24, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialRaches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, et al.
Iscience|March 16, 2021
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluationBrunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, et al.
Iscience|February 1, 2021
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster modelSreelekshmy Mohandas, Pragya D Yadav, Anita Shete-Aich, et al.
The Journal of Infection|August 13, 2022
First two cases of Monkeypox virus infection in travellers returned from UAE to India, July 2022Pragya D Yadav, Aravind Reghukumar, Rima R Sahay, et al.
The Indian Journal of Medical Research|July 3, 2020
Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgGGajanan Sapkal, Anita Shete-Aich, Rajlaxmi Jain, et al.
The Lancet. Infectious Diseases|March 11, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialRaches Ella, Siddharth Reddy, Harsh Jogdand, et al.
The Indian Journal of Medical Research|May 5, 2020
Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in IndiaVarsha Potdar, Sarah S Cherian, Gururaj Rao Deshpande, et al.
Lancet (London, England)|November 14, 2021
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddarth Reddy, William Blackwelder, et al.
Nature Medicine|February 22, 2023
When to update COVID-19 vaccine compositionRebecca Grant, Jilian A Sacks, Priya Abraham, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
The Indian Journal of Medical Research|May 5, 2020
First isolation of SARS-CoV-2 from clinical samples in IndiaPrasad Sarkale, Savita Patil, Pragya D Yadav, et al.
The Lancet. Infectious Diseases|January 24, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialRaches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, et al.
Iscience|March 16, 2021
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluationBrunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, et al.
Iscience|February 1, 2021
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster modelSreelekshmy Mohandas, Pragya D Yadav, Anita Shete-Aich, et al.
The Journal of Infection|August 13, 2022
First two cases of Monkeypox virus infection in travellers returned from UAE to India, July 2022Pragya D Yadav, Aravind Reghukumar, Rima R Sahay, et al.
The Indian Journal of Medical Research|July 3, 2020
Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgGGajanan Sapkal, Anita Shete-Aich, Rajlaxmi Jain, et al.
The Lancet. Infectious Diseases|March 11, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialRaches Ella, Siddharth Reddy, Harsh Jogdand, et al.
The Indian Journal of Medical Research|May 5, 2020
Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in IndiaVarsha Potdar, Sarah S Cherian, Gururaj Rao Deshpande, et al.
Lancet (London, England)|November 14, 2021
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddarth Reddy, William Blackwelder, et al.
Nature Medicine|February 22, 2023
When to update COVID-19 vaccine compositionRebecca Grant, Jilian A Sacks, Priya Abraham, et al.
Pageof 20